379 related articles for article (PubMed ID: 35015342)
1. Therapeutic opportunities for senolysis in cardiovascular disease.
Sweeney M; Cook SA; Gil J
FEBS J; 2023 Mar; 290(5):1235-1255. PubMed ID: 35015342
[TBL] [Abstract][Full Text] [Related]
2. Senescent Cells: A Therapeutic Target in Cardiovascular Diseases.
Suda M; Paul KH; Minamino T; Miller JD; Lerman A; Ellison-Hughes GM; Tchkonia T; Kirkland JL
Cells; 2023 May; 12(9):. PubMed ID: 37174697
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Potential of Senolytics in Cardiovascular Disease.
Dookun E; Passos JF; Arthur HM; Richardson GD
Cardiovasc Drugs Ther; 2022 Feb; 36(1):187-196. PubMed ID: 32979174
[TBL] [Abstract][Full Text] [Related]
4. Senescence and senolytics in cardiovascular disease: Promise and potential pitfalls.
Owens WA; Walaszczyk A; Spyridopoulos I; Dookun E; Richardson GD
Mech Ageing Dev; 2021 Sep; 198():111540. PubMed ID: 34237321
[TBL] [Abstract][Full Text] [Related]
5. Targeting cellular senescence with senotherapeutics: senolytics and senomorphics.
Zhang L; Pitcher LE; Prahalad V; Niedernhofer LJ; Robbins PD
FEBS J; 2023 Mar; 290(5):1362-1383. PubMed ID: 35015337
[TBL] [Abstract][Full Text] [Related]
6. A guide to senolytic intervention in neurodegenerative disease.
Lee S; Wang EY; Steinberg AB; Walton CC; Chinta SJ; Andersen JK
Mech Ageing Dev; 2021 Dec; 200():111585. PubMed ID: 34627838
[TBL] [Abstract][Full Text] [Related]
7. Potential Clinical Implications of Senotherapies for Cardiovascular Disease.
Suda M; Katsuumi G; Tchkonia T; Kirkland JL; Minamino T
Circ J; 2024 Feb; 88(3):277-284. PubMed ID: 37880106
[TBL] [Abstract][Full Text] [Related]
8. The Emergence of Senescent Surface Biomarkers as Senotherapeutic Targets.
Rossi M; Abdelmohsen K
Cells; 2021 Jul; 10(7):. PubMed ID: 34359910
[TBL] [Abstract][Full Text] [Related]
9. From the divergence of senescent cell fates to mechanisms and selectivity of senolytic drugs.
L'Hôte V; Mann C; Thuret JY
Open Biol; 2022 Sep; 12(9):220171. PubMed ID: 36128715
[TBL] [Abstract][Full Text] [Related]
10. Senolytics and senomorphics: Natural and synthetic therapeutics in the treatment of aging and chronic diseases.
Lagoumtzi SM; Chondrogianni N
Free Radic Biol Med; 2021 Aug; 171():169-190. PubMed ID: 33989756
[TBL] [Abstract][Full Text] [Related]
11. Quercetin and dasatinib, two powerful senolytics in age-related cardiovascular disease.
Nieto M; Konigsberg M; Silva-Palacios A
Biogerontology; 2024 Feb; 25(1):71-82. PubMed ID: 37747577
[TBL] [Abstract][Full Text] [Related]
12. Skeletal muscle aging, cellular senescence, and senotherapeutics: Current knowledge and future directions.
Englund DA; Zhang X; Aversa Z; LeBrasseur NK
Mech Ageing Dev; 2021 Dec; 200():111595. PubMed ID: 34742751
[TBL] [Abstract][Full Text] [Related]
13. Senotherapeutics for mesenchymal stem cell senescence and rejuvenation.
Wong PF; Dharmani M; Ramasamy TS
Drug Discov Today; 2023 Jan; 28(1):103424. PubMed ID: 36332835
[TBL] [Abstract][Full Text] [Related]
14. Cellular Senescence and Senolytic Agents: Recent Updates on Their Role and Applications.
Chandrakar L; Ambatwar R; Khatik GL
Curr Top Med Chem; 2024; 24(2):157-178. PubMed ID: 38037999
[TBL] [Abstract][Full Text] [Related]
15. Obesity, Senescence, and Senolytics.
Chaib S; Tchkonia T; Kirkland JL
Handb Exp Pharmacol; 2022; 274():165-180. PubMed ID: 34697668
[TBL] [Abstract][Full Text] [Related]
16. Senotherapeutics to Counteract Senescent Cells Are Prominent Topics in the Context of Anti-Ageing Strategies.
Calabrò A; Accardi G; Aiello A; Caruso C; Galimberti D; Candore G
Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339070
[TBL] [Abstract][Full Text] [Related]
17. Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans.
Zhu Y; Prata LGPL; Gerdes EOW; Netto JME; Pirtskhalava T; Giorgadze N; Tripathi U; Inman CL; Johnson KO; Xue A; Palmer AK; Chen T; Schaefer K; Justice JN; Nambiar AM; Musi N; Kritchevsky SB; Chen J; Khosla S; Jurk D; Schafer MJ; Tchkonia T; Kirkland JL
EBioMedicine; 2022 Mar; 77():103912. PubMed ID: 35292270
[TBL] [Abstract][Full Text] [Related]
18. Senolytics Cocktail Dasatinib and Quercetin Alleviate Human Umbilical Vein Endothelial Cell Senescence via the TRAF6-MAPK-NF-κB Axis in a YTHDF2-Dependent Manner.
Fan T; Du Y; Zhang M; Zhu AR; Zhang J
Gerontology; 2022; 68(8):920-934. PubMed ID: 35468611
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and limitations of senolysis in atherosclerosis.
Garrido AM; Kaistha A; Uryga AK; Oc S; Foote K; Shah A; Finigan A; Figg N; Dobnikar L; Jørgensen H; Bennett M
Cardiovasc Res; 2022 Jun; 118(7):1713-1727. PubMed ID: 34142149
[TBL] [Abstract][Full Text] [Related]
20. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease.
Hickson LJ; Langhi Prata LGP; Bobart SA; Evans TK; Giorgadze N; Hashmi SK; Herrmann SM; Jensen MD; Jia Q; Jordan KL; Kellogg TA; Khosla S; Koerber DM; Lagnado AB; Lawson DK; LeBrasseur NK; Lerman LO; McDonald KM; McKenzie TJ; Passos JF; Pignolo RJ; Pirtskhalava T; Saadiq IM; Schaefer KK; Textor SC; Victorelli SG; Volkman TL; Xue A; Wentworth MA; Wissler Gerdes EO; Zhu Y; Tchkonia T; Kirkland JL
EBioMedicine; 2019 Sep; 47():446-456. PubMed ID: 31542391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
